Cytokinetics CYTK D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.2%

Eli LillyLLY

$534M+11.7%

Lexicon PharmaceuticalsLXRX

$102K-42.0%

Edgewise Therapeutics, Inc.EWTX

$537K+4.7%

Capricor TherapeuticsCAPR

$534.67K+31.9%

Kiniksa Pharmaceuticals International, plcKNSA

$472K+31.8%

FAQ

What is Cytokinetics's D&A?

Cytokinetics (CYTK) reported D&A of $3.63M in Q2 2026.

How has Cytokinetics's D&A changed year-over-year?

Cytokinetics's D&A increased by 58.9% year-over-year, from $2.29M to $3.63M.

What is the long-term trend for Cytokinetics's D&A?

Over 4 years (2021 to 2025), Cytokinetics's D&A has grown at a 45.2% compound annual growth rate (CAGR), from $2.28M to $10.13M.

What does D&A mean?

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.